SAB 生物治療公司

SecuritySABS / SAB Biotherapeutics, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership1,847,136 shares
Latest Disclosed Value $ 6,908,288
Vanguard Group Inc reports 405.02% increase in ownership of SABS / SAB Biotherapeutics, Inc.

On January 29, 2026 - Vanguard Group Inc filed a 13F-HR form disclosing ownership of 1,847,136 shares of SAB Biotherapeutics, Inc. (US:SABS) valued at $6,908,289 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 7, 2025 disclosing 365,753 shares of SAB Biotherapeutics, Inc.. This represents a change in shares of 405.02% during the quarter. The current value of the position is $6,409,562 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F SAB BIOTHERAPEUTICS COM NEW 78397T202 1,847,136 1,481,383 405.02 6,908 839.86 0.0001
2025-11-07 2025-09-30 13F SAB BIOTHERAPEUTICS COM NEW 78397T202 365,753 83,382 29.53 735 48.79 0.0000
2025-08-11 2025-06-30 13F SAB BIOTHERAPEUTICS COM NEW 78397T202 282,371 4,861 1.75 494 32.09 0.0000
2025-05-09 2025-03-31 13F SAB BIOTHERAPEUTICS COM NEW 78397T202 277,510 135 0.05 375 -64.68 0.0000
2025-02-11 2024-12-31 13F SAB BIOTHERAPEUTICS COM NEW 78397T202 277,375 1,039 0.38 1,060 41.96 0.0000
2024-11-13 2024-09-30 13F SAB BIOTHERAPEUTICS COM NEW 78397T202 276,336 0 0.00 746 -12.85 0.0000
2024-08-13 2024-06-30 13F SAB BIOTHERAPEUTICS COM NEW 78397T202 276,336 100,002 56.71 857 7.00 0.0000
2024-05-10 2024-03-31 13F SAB BIOTHERAPEUTICS COM NEW 78397T202 176,334 176,334 801 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.